Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Safety and Immunogenicity of NVGH Vi-CRM197 Vaccine Against S. Typhi in Adults
NCT01193907Phase 2Completed
- Sponsor
- Novartis
- Start
- Oct 2010
- Primary completion
- Nov 2010
- Modality
- Vaccines & Immunotherapeutics
- Countries
- 1
01
Overview
A Phase 2 trial of Vi-CRM197 in typhoid fever, sponsored by Novartis. Started Oct 2010; status: completed.
02
Drugs
Vi-CRM197
03
Conditions
typhoid fever
Beyond the preview
Go deeper on NCT01193907.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01193907.